Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : INCR -- Incara Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (185)	10/22/2002 1:55:08 PM
From: keokalani'nui	Respond to of 196

Not long ago they said liver was their best program.

To: tuck who wrote (185)	10/22/2002 2:49:57 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 196

1. I can't profit much from trading stocks down in the dime range. 2. They've ignored chemistry for so long that I can't imagine future insights. Pedigree...... Interneuron, driving right back to Rosenwald. Tradition..... let the project slip to practical disrepair, allow outside-but-owe-you-a-favor-in-the-future investors to buy it on the cheap, wrap it for (or in) a new company, and drive it for what it's worth. Duncan didn't seem, to me, to fit the mold. Too bad that he'll now have little choice but to follow the old pattern.